| 总人数 | 出现脑转移人数 | Gray检验 | Fine-Gray检验 | |||||
12个月CIF | 24个月CIF | P | SHR | 95%CI | P | ||||
性别 | 男 | 520 | 107 | 0.161 | 0.273 | 0.028 | 0.834 | 0.489~1.422 | 0.580 |
女 | 418 | 115 | 0.200 | 0.393 | |||||
年龄 | ≥65 | 307 | 79 | 0.178 | 0.299 | 0.782 | 0.947 | 0.615~1.456 | 0.830 |
<65 | 631 | 143 | 0.179 | 0.352 | |||||
PS | 0 | 84 | 15 | 0.138 | 0.200 | 0.299 | 1.387 | 0.889~2.163 | 0.230 |
1 | 727 | 175 | 0.174 | 0.352 | |||||
2 | 102 | 27 | 0.256 | 0.300 | |||||
3 | 25 | 5 | 0.128 | 0.225 | |||||
吸烟 | 0 | 501 | 132 | 0.202 | 0.372 | 0.040 | 1.208 | 0.728~2.003 | 0.540 |
1 | 437 | 90 | 0.152 | 0.275 | |||||
EGFR敏感位点 | 野生 | 578 | 99 | 0.140 | 0.247 | <0.001 | 1.512 | 0.988~2.314 | 0.110 |
突变 | 360 | 123 | 0.238 | 0.448 | |||||
T分期 | 1 | 199 | 42 | 0.083 | 0.188 | <0.001 | 0.731 | 0.537~0.995 | 0.094 |
2 | 383 | 67 | 0.138 | 0.204 | |||||
3 | 151 | 58 | 0.326 | 0.737 | |||||
4 | 205 | 55 | 0.307 | 0.877 | |||||
N分期 | 0 | 199 | 36 | 0.076 | 0.158 | <0.001 | 0.629 | 0.502~0.787 | <0.001 |
1 | 124 | 33 | 0.126 | 0.321 | |||||
2 | 327 | 59 | 0.158 | 0.344 | |||||
3 | 288 | 94 | 0.310 | 0.558 | |||||
颅外转移 | 无 | 474 | 98 | 0.115 | 0.238 | <0.001 | 0.123 | 0.039~0.393 | 0.003 |
有 | 464 | 124 | 0.260 | 0.522 | |||||
治疗 | 支持治疗 | 17 | 6 | 0.373 | NA | <0.001 | 0.712 | 0.524~0.969 | 0.070 |
手术±化疗 | 250 | 50 | 0.118 | 0.229 | |||||
放疗±化疗 | 404 | 85 | 0.145 | 0.316 | |||||
单化疗 | 133 | 25 | 0.216 | 0.370 | |||||
单TKI | 134 | 56 | 0.372 | 0.644 |